Amiloride reduces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma

作者：Yuanyuan Bai, Yiqing You, Daoxun Chen, Yongmei Chen, Zhenjie Yin, Shangfan Liao, Bingyong You, Dongming Lu, Yingming Sun, Lixian Wu, Yongyang Wu · 发表于：iScience · 年份：2024 · DOI：10.1016/j.isci.2024.109997 · 被引用次数：5 · 研究领域：Renal cell carcinoma treatment、Cancer, Hypoxia, and Metabolism、Cancer, Lipids, and Metabolism

The kidney is a vital organ responsible for water and sodium metabolism, while the primary function of amiloride is to promote the excretion of water and sodium. We investigated amiloride enhanced the sunitinib sensitivity in RCC. We found both sunitinib and amiloride displayed cytotoxicity and exerted the synergy effect in RCC cells in vivo and in vitro arrays. Protein expression profiles were screened via MS/TMT, revealing that FN3K was upregulated in the sunitinib group, and rescued in amiloride and the combination administration. Exogenous FN3K could promote proliferation, invasion and metastasis and decrease the sensitivity of Caki-1 cells to sunitinib, also, exogenous FN3K up-regulated VEGFR2 expression and activated AKT/mTOR signal pathway. More FN3K and VEGFR2 accumulated in R-Caki-1 cells and rescued by amiloride treatment. Co-IP and IF confirmed the interaction between FN3K and VEGFR2. In conclusion, FN3K depletion mediated VEGFR2 disruption promotes amiloride synergized the anti-RCC activity of sunitinib.